Showing results (91-100 of 342) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 29, 2008
Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?P S Sorensen, N Koch-Henriksen, E M Flachs, et al.
Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP|February 13, 2007
Tissue distribution of cytochrome P450 3A (CYP3A) in brushtail possums (Trichosurus vulpecula) exposed to Eucalyptus terpenesJennifer S Sorensen, Kristian C Forbey, Robert L Tanquay, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|February 14, 2013
Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacyHanne B Albert, Joan S Sorensen, Berit Schiott Christensen, et al.
Acta Endocrinologica|November 1, 1976
The insulin receptor in normal and obese personsH Beck-Nielsen, O Pedersen, J P Bagger, et al.
Cancers|December 9, 2023
Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint InhibitorSimone Stensgaard, Astrid Thomsen, Sofie Helstrup, et al.
British Journal of Sports Medicine|August 23, 2008
Antibiotic treatment in patients with low-back pain associated with Modic changes Type 1 (bone oedema): a pilot studyH B Albert, C Manniche, J S Sorensen, et al.
IEEE Transactions on Medical Imaging|April 9, 2008
Accelerating the nonequispaced fast Fourier transform on commodity graphics hardwareT S Sorensen, T Schaeffter, K O Noe, et al.
Scandinavian Journal of Immunology|July 27, 2006
Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosisM Krakauer, P S Sorensen, M Khademi, et al.
Melanoma Research|June 5, 2004
S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanomaHenrik Schmidt, Boe S Sorensen, Ebba Nexo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2009
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosisN Koch-Henriksen, P S Sorensen, K Bendtzen, et al.
Pageof 35